Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR inhibitor(s)

To assess the clinical efficacy of RAD001, based on the evaluation of objective tumor response rate (RR)

Lung cancer is one of the most common malignancies in developed countries and accounts for millions of deaths worldwide. In 2000, the annual incidence of non-small cell lung cancer (NSCLC), which comprises 80% of all lung cancer cases, was 991,089 and the worldwide mortality was 882,495. Unfortunately, two-thirds of NSCLC patients have advanced disease (clinical stage IIIB/IV) and are considered incurable by surgery or chest radiation

Kusajili – Centralise les essais cliniques mondiaux